- Eli Lilly Stock Dives After Earnings Beat. Here’s Why. Barron’s
- Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says CNN
- Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity Eli Lilly and Company
- Lilly’s GLP-1 pill cuts body weight by 12.4% in trial, lagging Novo’s injection Reuters
- Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker ABC News
Source link
